Curaleaf (OTCMKTS:CURLF - Get Free Report) was upgraded by Roth Capital to a "strong-buy" rating in a report released on Sunday,Zacks.com reports. Roth Capital also issued estimates for Curaleaf's Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.21) EPS.
CURLF has been the topic of several other reports. Needham & Company LLC restated a "buy" rating and set a $6.25 price target on shares of Curaleaf in a report on Thursday, August 8th. Cormark downgraded Curaleaf from a "moderate buy" rating to a "hold" rating in a research note on Thursday, November 7th.
Read Our Latest Report on CURLF
Curaleaf Stock Performance
CURLF traded up $0.20 during trading on Friday, hitting $2.24. 1,374,771 shares of the company's stock were exchanged, compared to its average volume of 714,002. Curaleaf has a fifty-two week low of $1.64 and a fifty-two week high of $6.40. The business's 50 day moving average is $2.93 and its two-hundred day moving average is $3.75. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11.
About Curaleaf
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
